Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan.
Eur J Clin Microbiol Infect Dis. 2010 Apr;29(4):383-9. doi: 10.1007/s10096-009-0868-4. Epub 2010 Feb 13.
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in nosocomial staphylococcal infections in Taiwan has exceeded 50% since 2000. However, little relevant data has been available concerning vancomycin-intermediate S. aureus (VISA) and heteroresistant VISA (hVISA). We collected 1,000 MRSA isolates from ten medical center hospitals in Taiwan during 2003. All were initially screened for reduced susceptibility to vancomycin on brain heart infusion (BHI) agar containing 5 mg/L vancomycin. Among 34 MRSA isolates that grew on the screening plates, two VISA isolates (0.2%) and seven hVISA isolates (0.7%) were evident. Vancomycin-resistant S. aureus was not detected. The accessory gene regulator (agr) typing of all 1,000 MRSA strains were typed by multiplex polymerase chain reaction (PCR); 919 strains (91.9%) including the VISA and hVISA isolates belonged to agr group I, 78 strains (7.8%) were agr group II, two strains (0.2%) were agr group III, and one isolate (0.1%) was agr group IV. There was no relationship between sample sites and agr typing. In 2003, the incidence of hVISA and VISA in Taiwan was low. Continued surveillance is recommended, given the implementation of new Clinical and Laboratory Standards Institute (CLSI) criteria for S. aureus and the increasing clinical use of glycopeptides.
自 2000 年以来,台湾地区医院内耐甲氧西林金黄色葡萄球菌(MRSA)的流行率已经超过 50%。然而,有关中间耐万古霉素金黄色葡萄球菌(VISA)和异质耐药性 VISA(hVISA)的相关数据却很少。我们在 2003 年期间从台湾的十家医学中心医院收集了 1000 株 MRSA 分离株。所有这些分离株最初都在含有 5mg/L 万古霉素的脑心浸液(BHI)琼脂上进行了对万古霉素敏感性降低的初步筛选。在生长于筛选平板上的 34 株 MRSA 分离株中,有两株 VISA 分离株(0.2%)和七株 hVISA 分离株(0.7%)。未检测到万古霉素耐药的金黄色葡萄球菌。通过多重聚合酶链反应(PCR)对所有 1000 株 MRSA 菌株进行了辅助基因调节(agr)分型;包括 VISA 和 hVISA 分离株在内的 919 株(91.9%)菌株属于 agr 组 I,78 株(7.8%)为 agr 组 II,两株(0.2%)为 agr 组 III,一株(0.1%)为 agr 组 IV。菌株的样本来源与 agr 分型之间没有关系。2003 年,台湾 hVISA 和 VISA 的发生率较低。鉴于新的临床和实验室标准协会(CLSI)金黄色葡萄球菌标准的实施以及糖肽类药物的临床应用不断增加,建议继续进行监测。